{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:43:01Z","timestamp":1740148981135,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s12325-018-0740-y","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T09:21:45Z","timestamp":1530004905000},"page":"1251-1264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+\/HER2\u2212 Metastatic Breast Cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Annie","family":"Gu\u00e9rin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Gagnon-Sanschagrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hela","family":"Romdhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Kelkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polly","family":"Niravath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand A.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"740_CR1","unstructured":"American Cancer Society. Cancer facts & figures\u00a02017 2017. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2017.html . Accessed 26 July 2017."},{"key":"740_CR2","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D BK, Kosary CL, Yu M, et al. SEER Cancer statistics review, 1975-2014 Bethesda, MD: National Cancer Institute; 2017 based on November 2016 SEER data submission. https:\/\/seer.cancer.gov\/csr\/1975_2014\/ . Accessed 3 July 2017."},{"issue":"1","key":"740_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3747\/co.20.1316","volume":"20","author":"KI Pritchard","year":"2013","unstructured":"Pritchard KI, Gelmon KA, Rayson D, Provencher L, Webster M, McLeod D, et al. Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol. 2013;20(1):48\u201361.","journal-title":"Curr Oncol"},{"issue":"9","key":"740_CR4","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1177\/1049732315591787","volume":"26","author":"S Lewis","year":"2016","unstructured":"Lewis S, Willis K, Yee J, Kilbreath S. Living well? strategies used by women LIVING with metastatic breast cancer. Qual Health Res. 2016;26(9):1167\u201379.","journal-title":"Qual Health Res"},{"key":"740_CR5","unstructured":"NIH\u2014National Cancer Institute. Metastatic cancer. https:\/\/www.cancer.gov\/types\/metastatic-cancer ."},{"issue":"10063","key":"740_CR6","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","volume":"388","author":"JFR Robertson","year":"2016","unstructured":"Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500\u00a0mg versus anastrozole 1\u00a0mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997\u20133005.","journal-title":"Lancet"},{"key":"740_CR7","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology\u2014breast cancer version 3.2017 https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp . Accessed 8 Dec 2017."},{"key":"740_CR8","unstructured":"NIH\u2014National Cancer Institute. Hormone therapy for breast cancer https:\/\/www.cancer.gov\/types\/breast\/breast-hormone-therapy-fact-sheet . Accessed 13 Sept 2017."},{"issue":"3","key":"740_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10549-007-9606-8","volume":"108","author":"PL Bedard","year":"2008","unstructured":"Bedard PL, Freedman OC, Howell A, Clemons M. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? Breast Cancer Res Treat. 2008;108(3):307\u201317.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"740_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335.","journal-title":"Lancet Oncol"},{"issue":"18","key":"740_CR11","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738\u201348.","journal-title":"N Engl J Med"},{"issue":"25","key":"740_CR12","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384.","journal-title":"J Clin Oncol"},{"issue":"32","key":"740_CR13","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u201346.","journal-title":"J Clin Oncol"},{"key":"740_CR14","unstructured":"US Food and Drug Administration. IBRANCE\u00ae (palbociclib)\u2014highlights of prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207103s000lbl.pdf . Accessed 13 Sept 2017."},{"key":"740_CR15","unstructured":"US Food and Drug Administration. KISQALI\u00ae (ribociclib)\u2014highlights of prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209092s000lbl.pdf . Accessed 17 Nov 2017."},{"key":"740_CR16","unstructured":"US Food and Drug Administration. VERZENIO\u2122 (abemaciclib)\u2014Highlights of Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208716s000lbl.pdf . Accessed 17 Nov 2017."},{"issue":"24","key":"740_CR17","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1200\/JCO.2016.66.6313","volume":"34","author":"MK Accordino","year":"2016","unstructured":"Accordino MK, Wright JD, Vasan S, Neugut AI, Hillyer GC, Hu JC, et al. Use and costs of disease monitoring in women with metastatic breast cancer. J Clin Oncol. 2016;34(24):2820\u20136.","journal-title":"J Clin Oncol"},{"key":"740_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","volume":"22","author":"LM Spring","year":"2017","unstructured":"Spring LM, Zangardi ML, Moy B, Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4\/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist. 2017;22:1039\u201348.","journal-title":"Oncologist."},{"key":"740_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12282-017-0818-4","volume":"25","author":"L Kassem","year":"2017","unstructured":"Kassem L, Shohdy KS, Lasheen S, Abdel-Rahman O, Bachelot T. Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Breast Cancer. 2017;25:17\u201327.","journal-title":"Breast Cancer"},{"key":"740_CR20","doi-asserted-by":"publisher","unstructured":"Dalal AA, Gagnon-Sanschagrin P, Burne R, Guerin A, Gauthier G, Small T, et al. Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+\/HER2- Metastatic Breast Cancer. Adv Ther. 2018. https:\/\/doi.org\/10.1007\/s12325-018-0701-5 .","DOI":"10.1007\/s12325-018-0701-5"},{"issue":"11","key":"740_CR21","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"6","key":"740_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3747\/co.2007.156","volume":"14","author":"A Goldrick","year":"2007","unstructured":"Goldrick A, Olivotto IA, Alexander CS, Speers CH, Barnett J, Allan SJ, et al. Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer. Curr Oncol. 2007;14(6):227\u201333.","journal-title":"Curr Oncol"},{"issue":"11","key":"740_CR23","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","volume":"21","author":"H Mouridsen","year":"2003","unstructured":"Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101\u20139.","journal-title":"J Clin Oncol"},{"issue":"22","key":"740_CR24","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","volume":"18","author":"JM Nabholtz","year":"2000","unstructured":"Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18(22):3758\u201367.","journal-title":"Arimidex Study Group. J Clin Oncol"},{"issue":"35","key":"740_CR25","doi-asserted-by":"crossref","first-page":"57301","DOI":"10.18632\/oncotarget.10254","volume":"7","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Shao Z, Shen K, Li L, Feng J, Tong Z, et al. Fulvestrant 500\u00a0mg vs 250\u00a0mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. Oncotarget. 2016;7(35):57301\u20139.","journal-title":"Oncotarget"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-018-0740-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0740-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0740-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T08:56:27Z","timestamp":1604480187000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-018-0740-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0740-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"10 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}